Palladon (Hydromorphone Hydrochloride)

Hydromorphone Hydrochloride is an opioid that acts on the central nervous system to relieve pain across several clinical settings.

• Acute postoperative pain: provides rapid analgesia following surgery.
• Cancer‑related pain: helps control persistent pain associated with malignant disease.
• Severe chronic non‑cancer pain: used when other analgesics are insufficient.

• Hydromorphone binds selectively to μ‑opioid receptors in the central nervous system, mimicking endogenous opioids. This activation reduces neuronal excitability and inhibits transmission of nociceptive signals, producing analgesia and a sense of well‑being.

Adverse reactions may occur with hydromorphone use and should be monitored.

Common Side Effects

• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Constipation: reduced bowel motility leading to hard stools.
• Drowsiness or sedation: increased sleepiness or reduced alertness.
• Dizziness: sensation of light‑headedness or imbalance.
• Dry mouth: reduced salivation causing oral discomfort.
• Sweating: increased perspiration without exertion.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing that can be life‑threatening.
• Severe hypotension: marked drop in blood pressure.
• Bradycardia: unusually slow heart rate.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Confusion or delirium: altered mental status.
• Dependence or withdrawal: signs of physical dependence with prolonged use.

When prescribing hydromorphone, clinicians should consider several safety factors.

• Assess pain severity: confirm that opioid therapy is appropriate for the level of pain.
• Evaluate patient history: screen for respiratory disorders, head injury, or substance abuse.
• Monitor for sedation: watch for excessive drowsiness, especially when combined with other CNS depressants.
• Adjust for renal/hepatic impairment: dose may need modification in patients with organ dysfunction.
• Educate on constipation: advise prophylactic laxatives and fluid intake.
• Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Hydromorphone may interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Benzodiazepines: combined use can cause profound respiratory depression.
• Other opioids: additive central nervous system depression increases overdose risk.
• CNS depressants (e.g., barbiturates, alcohol): may intensify sedation and respiratory effects.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise hydromorphone plasma levels.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce analgesic effect.
• Anticholinergic agents: may worsen constipation.
• Diuretics: can enhance hypotensive effects.
• Serotonergic drugs: risk of serotonin syndrome when combined with certain antidepressants.